Rankings
▼
Calendar
UTHR Q1 2025 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena
UTHR
United Therapeutics Corporation
$24B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$794M
+17.2% YoY
Gross Profit
$702M
88.4% margin
Operating Income
$383M
48.2% margin
Net Income
$322M
40.6% margin
EPS (Diluted)
$6.63
QoQ Revenue Growth
+7.9%
Cash Flow
Operating Cash Flow
$461M
Free Cash Flow
$386M
Stock-Based Comp.
$32M
Balance Sheet
Total Assets
$7.7B
Total Liabilities
$937M
Stockholders' Equity
$6.8B
Cash & Equivalents
$1.9B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$794M
$678M
+17.2%
Gross Profit
$702M
$605M
+16.1%
Operating Income
$383M
$356M
+7.4%
Net Income
$322M
$307M
+5.1%
Revenue Segments
Tyvaso
$466M
59%
Remodulin
$138M
17%
Orenitram
$121M
15%
Unituxin
$58M
7%
Adcirca
$6M
1%
Product and Service, Other
$5M
1%
Geographic Segments
UNITED STATES
$750M
94%
Non-US
$45M
6%
← FY 2025
All Quarters
Q2 2025 →